Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
69 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
20s Proteasome - Pipeline Review, H2 2016 Summary Global Markets Direct's, '20s Proteasome - Pipeline Review, H2 2016', provides in depth analysis on 20s Proteasome targeted pipeline therapeutics. The report provides comprehensive information on the 20s Proteasome , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 20s Proteasome targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for 20s Proteasome - The report reviews 20s Proteasome targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in 20s Proteasome targeted therapeutics and enlists all their major and minor projects - The report assesses 20s Proteasome targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to 20s Proteasome targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for 20s Proteasome - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding 20s Proteasome development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 20s Proteasome Overview 6 Therapeutics Development 7 20s Proteasome - Products under Development by Stage of Development 7 20s Proteasome - Products under Development by Therapy Area 8 20s Proteasome - Products under Development by Indication 9 20s Proteasome - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 20s Proteasome - Products under Development by Companies 13 20s Proteasome - Therapeutics Assessment 16 Assessment by Monotherapy/Combination Products 16 Assessment by Mechanism of Action 17 Assessment by Route of Administration 18 Assessment by Molecule Type 20 20s Proteasome - Companies Involved in Therapeutics Development 21 Amgen Inc. 21 LG Life Science LTD. 23 Triphase Accelerator Corporation 24 20s Proteasome - Drug Profiles 25 carfilzomib - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 marizomib - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 oprozomib - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Small Molecules to Inhibit 20S Proteasome for Multiple Myeloma and Solid Tumor - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 VPE-001 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 VPEA-002 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 VPEA-004 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 VR-23 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 20s Proteasome - Dormant Projects 49 20s Proteasome - Featured News & Press Releases 50 Sep 27, 2016: Amgen Announces Top-Line Results From Phase 3 KYPROLIS (Carfilzomib) CLARION Study In Newly Diagnosed Multiple Myeloma Patients 50 Sep 07, 2016: ONO Launches KYPROLIS for Intravenous Injection 10 mg and 40 mg Proteasome Inhibitor 51 Sep 07, 2016: ONO Submits Supplemental New Drug Application in Japan for "KYPROLIS for Intravenous Injection 10 mg and 40 mg", a Proteasome Inhibitor, for Relapsed or Refractory Multiple Myeloma 51 Jul 04, 2016: ONO Receives Manufacturing and Marketing Approval in Japan for KYPROLIS, a Proteasome Inhibitor, in Relapsed or Refractory Multiple Myeloma 52 Jul 03, 2016: European Commission Approves Extended Indication For Amgen's Kyprolis (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients 53 Jun 10, 2016: New Analyses From Pivotal Phase 3 Studies Show Kyprolis (Carfilzomib) Allows Patients With Relapsed Multiple Myeloma To Live Longer Without Disease Progression 55 Jun 09, 2016: Preliminary data for pre-kidney transplant being presented June 13 59 Jun 06, 2016: New Phase 3 Secondary Analysis Shows Progression-Free Survival Benefit In Early Relapsing Multiple Myeloma Patients Treated With Kyprolis (Carfilzomib)-Based Regimen 60 Jun 04, 2016: Triphase Accelerator Corporation Announces Positive Results of Phase 1 Trial of Marizomib and Bevacizumab in Malignant Glioma 61 Jun 03, 2016: Amgen Announces Launch Of KYPROLIS (carfilzomib) CENTRAL, An Online News Resource Demonstrating The Impact Of Relapsed Multiple Myeloma On The Lives Of Patients And Caregivers 62 May 27, 2016: Amgen Receives Positive CHMP Opinion To Extend Indication Of Kyprolis (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma 62 May 26, 2016: Kyprolis (Carfilzomib) Demonstrates Economic Value In Relapsed Or Refractory Multiple Myeloma Manuscript Published In "Journal of Medical Economics" 63 May 19, 2016: Amgen Highlights Data on Kyprolis at 21st Congress Of The European Hematology Association 64 May 18, 2016: Amgen To Present Data on Kyprolis (carfilzomib) At ASCO 2016 66 Apr 19, 2016: Triphase Accelerator Corporation Announces Positive Interim Results of Phase 1 Trial of Marizomib and Bevacizumab in Malignant Glioma 67 Appendix 68 Methodology 68 Coverage 68 Secondary Research 68 Primary Research 68 Expert Panel Validation 68 Contact Us 68 Disclaimer 69
List of Tables
Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Indication, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Early Stage Products, H2 2016 12 Number of Products under Development by Companies, H2 2016 13 Products under Development by Companies, H2 2016 14 Products under Development by Companies, H2 2016 (Contd..1) 15 Assessment by Monotherapy/Combination Products, H2 2016 16 Number of Products by Stage and Mechanism of Action, H2 2016 17 Number of Products by Stage and Route of Administration, H2 2016 19 Number of Products by Stage and Molecule Type, H2 2016 20 Pipeline by Amgen Inc., H2 2016 22 Pipeline by LG Life Science LTD., H2 2016 23 Pipeline by Triphase Accelerator Corporation, H2 2016 24 Dormant Projects, H2 2016 49
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
